Gantacurium Chloride

Phase II Pending

A benzylisoquinoline alkaloid potentially used as adjuncts to anesthesia.

Research Code AV 430A; GW-280430

CAS No. 213998-46-0(Gantacurium chloride)  758669-50-0(GW-0430)

Naproxen Etemesil

Phase III Pending

A cyclooxygenase (COX) inhibitor potentially for the treatment of osteoarthritis.

Research Code LT-NS-001; LT-NS001; MX-1094

CAS No. 385800-16-8(Naproxen etemesil)

6beta-Naltrexol

Phase I Active

An opioid receptor antagonist potentially for the treatment of opioid-induced bowel dysfunction and opioid dependency.

Research Code AIKO-150; AIKO-151; NTXOL

CAS No. 49625-89-0(6beta-Naltrexol)

Bromopyruvate

Preclinical Pending

A hexokinase 2, MASP2 protein and pyruvate dehydrogenase complex inhibitor potentially for the treatment of pancreatic cancer, breast cancer, lung cancer and ovarian cancer.

Research Code 3-BrPA; NSC-11731; NSC-62343; PSL-001

CAS No. 1113-59-3(Bromopyruvate)

Nifeviroc

Phase II Discontinued

A C-C motif chemokine receptor 5 (CCR5) antagonist potentially for the treatment of HIV infection.

Research Code TD-0232

CAS No. 934740-33-7(Nifeviroc)

PUR-118

Phase I Discontinued

An Immunomodulator potentially for the treatment of cystic fibrosis, chronic obstructive pulmonary disease (COPD), asthma and influenza virus infection.

Research Code PUR-118; PUR118

CAS No.

AEOL-10150

Phase I Active

A superoxide dismutase (SOD) mimetics for the treatment of solid tumours and idiopathic pulmonary fibrosis (IPF).

Research Code AEOL-10150; Mn-TDEIP

CAS No. 286475-30-7(Aeol 10150)  791770-55-3(AEOL-10150)

Brimapitide

Phase III Active

A mitogen-activated protein kinase 8 inhibitor potentially for the treatment of ocular inflammation.

Research Code AM-111

CAS No. 1445179-97-4(Brimapitide)

ASP-7035

Phase II Active

A vasopressin V2 receptor (AVPR2) agonist potentially for the treatment of nocturia.

Research Code ASP-7035

CAS No.

Pivaloyloxymethyl Butyrate

Phase II Discontinued

A histone deacetylase (HDAC) inhibitor potentially for the treatment of chronic lymphocytic leukaemia, liver cancer, malignant melanoma and non-small cell lung cancer.

Research Code AN-9

CAS No. 122110-53-6(Pivanex)

Gallium Maltolate

Phase II Discontinued

A ribonucleotide reductase (RNR) inhibitor potentially for the treatment of prostate cancer, bladder cancer, lymphoma and Paget's disease.

Research Code

CAS No. 108560-70-9(Gallium maltolate)

BAT-8001

Phase I Active

A HER2 targeted antibody conjugated to Batansine potentially for the treatment of cancer.

Research Code BAT-8001

CAS No.

DTS-108

Phase I Pending

A DNA topoisomerase I inhibitor potentially for the treatment of solid tumors.

Research Code DTS-108

CAS No. 951792-83-9(DTS-108)

Pyragrel Sodium

Phase I Active

A drug potentially for the treatment of cerebral infarction.

Research Code TSF; MC002

CAS No. 1613638-20-2(TSF)  1018438-91-9(TSF Free)

XY0206

Phase I Active

A drug potentially for the treatment of acute myeloid Leukemia (AML).

Research Code XY0206

CAS No.

巴替非班

Phase III Active

A glycoprotein IIb/IIIa antagonist potentially for the treatment of acute coronary syndrome (ACS).

Research Code BAT2094

CAS No. 710312-77-9(Batifiban)

Felbinac Trometamol

Phase I Pending

Felbinac trometamol is potentially for the treatment of pain and inflammation.

Research Code

CAS No. 935886-64-9(Felbinac Trometamol)  5728-52-9(Felbinac)

HY-021068

Phase I Active

A drug potentially for the treatment of ischemic stroke and other thromboembolism.

Research Code HY-021068

CAS No.

FF-21101-Y-90

Phase I Active

A Yttrium-90 labelled antibody targeting cadherin-3 potentially for the treatment of solid tumor.

Research Code FF-21101-Y-90

CAS No.

E-6201

Phase II Active

A FLT-3 and MEK1 inhibitor potentially for the treatment of acute lymphoblastic leukaemia (ALL), chronic myelomonocytic leukemia (CMML) and myelodysplastic syndrome (MDS).

Research Code E-6201

CAS No. 603987-35-5(E-6201)